Related Experiment Video
Updated: Aug 23, 2026
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
Treatment of HCC with pravastatin, octreotide, or gemcitabine--a critical evaluation
C Lersch1, R Schmelz, J Erdmann
1II. Department of Internal Medicine, Technical University of Munich, Klinikum Rechts der Isar, Munich, Germany. christian.lersch@lrz.tum.de
Background/Aims:
New perspectives in the treatment of advanced hepatocellular carcinomas have recently been inaugurated with the application of hydroxymethylglutaryl coenzyme A reductase inhibitors i.e. pravastatin, the somatostatin analogue octreotide, or the cytidine analogue gemcitabine. The present study aimed to evaluate these substances in patients with progressive tumor growth.
Methodology:
A total of 58 patients either received 3 x 200 microg/day octreotide for 2 months followed by 20mg octreotide LAR every 4 weeks (n=30) or 40-80 mg pravastatin (n=20) or 80-90 mg/m2 gemcitabine over 24 hours weekly in cycles of 4 weeks (n=8). Kaplan-Meier survival curves and the log-rank test were used for univariate comparison of sur vival.
Results:
The median overall survival of patients receiving octreotide was 5 months, of patients receiving pravastatin 7.2 months and of patients receiving gemcitabine 3.5 months. The difference between the pravastatin and the gemcitabine groups was significant. No WHO grade 3 or 4 side effects were seen in either group of patients.
Conclusions:
These results do not confirm those of former studies. Neither pravastatin, nor octreotide, nor gemcitabine did prolong the patients' median overall survival as compared to control groups reported by other authors. New therapeutic strategies have to be found for patients with advanced hepatocellular carcinomas.
Insights
This study found that pravastatin, octreotide, and gemcitabine did not improve overall survival in advanced hepatocellular carcinoma patients. New treatment strategies are needed for this condition.
Area of Science:
- Hepatocellular Carcinoma Research
- Oncology Drug Efficacy
Background:
- Advanced hepatocellular carcinoma (HCC) treatment explored new avenues with HMG-CoA reductase inhibitors (pravastatin), somatostatin analogues (octreotide), and cytidine analogues (gemcitabine).
- Previous studies suggested potential benefits of these agents in HCC treatment.
Purpose of the Study:
- To evaluate the efficacy of pravastatin, octreotide, and gemcitabine in patients with progressive advanced hepatocellular carcinoma.
- To determine if these agents could prolong overall survival in HCC patients.
Main Methods:
- A total of 58 patients with advanced HCC were treated with either octreotide (n=30), pravastatin (n=20), or gemcitabine (n=8).
- Treatment regimens varied: octreotide (initial oral, then LAR injections), pravastatin (40-80 mg), and gemcitabine (80-90 mg/m2 weekly).
- Kaplan-Meier survival analysis and log-rank tests were employed for survival comparisons.
Main Results:
- Median overall survival was 5 months for octreotide, 7.2 months for pravastatin, and 3.5 months for gemcitabine.
- A significant difference in survival was observed between the pravastatin and gemcitabine groups.
- No WHO grade 3 or 4 side effects were reported in any treatment group.
Conclusions:
- The study did not confirm previous findings suggesting improved survival with these agents in advanced HCC.
- Pravastatin, octreotide, and gemcitabine failed to prolong median overall survival compared to historical control groups.
- Novel therapeutic strategies are required for the management of advanced hepatocellular carcinoma.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...